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ABSTRACT
Introduction: Success rates for treatment of extensively drug resistant tuberculosis (XDR-TB) are low
due to limited treatment options, delayed diagnosis and inadequate health care infrastructure.
Areas covered: This review analyses existing programmes of prevention, diagnosis and treatment of
XDR-TB. Improved diagnostic procedures and rapid molecular tests help to select appropriate drugs and
dosages. Drugs dosages can be further tailored to the specific conditions of the patient based on
quantitative susceptibility testing of the M. tuberculosis isolate and use of therapeutic drug monitoring.
Pharmacovigilance is important for preserving activity of the novel drugs bedaquiline and delamanid.
Furthermore, biomarkers of treatment response must be developed and validated to guide therapeutic
decisions.
Expert commentary: Given the currently poor treatment outcomes and the association of XDR-TB with
HIV in endemic regions, a more patient oriented approach regarding diagnostics, drug selection and
tailoring and treatment evaluation will improve treatment outcome. The different areas of expertise
should be covered by a multidisciplinary team and may involve the transition of patients from
hospitalized to home or community-based treatment.
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Tuberculosis (TB), caused by Mycobacterium tuberculosis
(MTB), is now the leading cause of death from an infectious
disease worldwide. Around 1.5 million of the 9.6 million
people who developed TB died from this disease in 2014
[1]. Emergence and spread of multidrug-resistant (MDR) MTB
strains affect about half a million people worldwide
annually. MDR-TB is defined as resistance to isoniazid and
rifampicin. The incidence differs by geographic region and
ranges from 3.3% in newly diagnosed cases to 20% in
previously treated patients [1]. Even more worrisome is the
average incidence of MDR-TB in retreatment cases in
Belarus of 69% [1]. Approximately 34% of newly diagnosed
TB patients have MDR-TB [1], which reflects the importance
of transmission of MDR-Tb strains. Extensively drug-resistant
TB (XDR-TB) is defined by MDR-TB with additional resistance
to a fluoroquinolone and a second-line injectable drug
(amikacin, kanamycin, or capreomycin). Especially, the
spread of MDR/XDR-TB strains of the Beijing genotype is
of a great concern [2]. Treatment success of MDR-TB is
generally around 50%, lower (20%) and higher success
rates (80%) have been reported depending upon comorbid-
ities and available diagnostics and available drugs within
these cohorts [1,3]. Treatment becomes truly difficult in
cases where the fluoroquinolones or injectables cannot be
used and the oral bacteriostatic drugs were the only treat-
ment options left. Success rates for XDR-TB treatment are
therefore generally quite low; those with treatment failure
remain at risk of transmitting infection, and those able to be
microbiologically cured can suffer considerable morbidity
including chronic lung disease and permanent treatment-
related adverse events[4]. Two novel drugs, bedaquiline and
delamanid have recently been approved for use within
some treatment programs, while other antimicrobial agents
licensed for other infections are often used in combination
or as a last resort [5–7]. This reviews aims to give a concise
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overview on the new developments in prevention, diagno-
sis, and treatment of XDR-TB.
2. XDR-TB care as part of TB program; current
situation
The dimension and order of magnitude of the emerging XDR-
TB was for the first time realized only when the so-called
‘Tugela Ferry outbreak’ was reported in 2006 and stimulated
concerted global action. In this first report, 52/53 XDR-TB
inpatients succumbed to their infection within a median of
16 days and 44/44 patients tested were HIV coinfected [8].
Important for a positive treatment outcome in MDR/XDR-TB
is that those patients diagnosed are appropriately ‘channeled’
toward optimal care: a study from South Africa on MDR/XDR-
TB patients demonstrated that tracing patients following
establishment of a diagnosis is of the utmost importance.
The most frequent reason for non-referral of diagnosed
patients for specialist care was loss to follow-up [9].
Outcome determinants in XDR-TB patients are, not limited
to HIV coinfection or the specific therapeutic regimens
applied, but include also overall the access to drugs [10], the
utilization of care which can often be hampered by stigma
[11], and the level of care available. High levels of care for
drug-resistant TB or among HIV coinfected patients do not
necessarily need to be hospitalized [12]. Demands for treat-
ment programs include quality-assured drugs, regimens being
based on an adequate number, and the selection of effective
drugs given for an appropriate duration [13].
Whilst the role of individual drugs is not ascertained [13], it
has been suggested that in areas of high prevalence where
drug-susceptibility testing may be incomplete, that the use of
drugs which are not widely used in this particular setting is an
essential contributor to success [14]. Although increasing resis-
tance from MDR to XDR-TB and has been associated with
stepwise increase in poor outcome, and weighted relative
risks for each drug have been ascribed [15,16].
In some well-resourced settings with low drug-resistant TB
endemicity, rather than novel drugs, meticulous therapeutic
drug monitoring (TDM) [17] and adverse event assessment
alongside repeated resistance assessments are major determi-
nants associated with positive treatment outcomes [3].
Standard therapy for drug-sensitive TB follows established
guidelines; however, to date, globally harmonized treatment
standards for MDR-TB and XDR-TB in particular do not exist.
The global surveillance data on TB drug resistance has signifi-
cantly improved in detail and hence accuracy over the past
couple of years, as a consequence of higher coverage for drug
susceptibility testing [1]. Limited resources are an obvious
reason for not getting close to optimal diagnosis and treat-
ment of particular higher degrees of MDR/XDR-TB in most
settings. WHO has issued guidelines for programmatic man-
agement of TB alongside with a comprehensive handbook
that details all treatment aspects of MDR/XDR-TB [18,19].
Treatment should be either on an in- or outpatient basis (a
recent systematic review and meta-analysis of hospital- versus
ambulatory-based management of multidrug-resistant TB did
not yield statistically significant differences for all the
outcomes considered) [20]. Nevertheless specialist guidance
and within the framework of a national program to warrant
optimal treatment regimen design, infection control, as well as
contact tracing standards are essential elements.
With regard to treatment access, support and as a result
favorable outcomes, WHO suggested as one of the main
reasons for inadequate access to diagnosis and treatment of
DR-TB, that the programmatic management of DR-TB (PMDT)
is often too centralized; with hospital-based models of care
being considered a barrier to PMDT expansion due to their
dependency on hospitals or referral centers. Wider use of
ambulatory care is considered as the way forward [1].
An example for standardized, elaborated treatment guide-
lines in a high burden country are the South-African guide-
lines [21]. An example for a highly individualized approach in
an affluent, low-endemic setting is the Netherlands [3].
However, for clearly understandable reasons, given the com-
plexity of the issue and the difficulty of obtaining unambig-
uous results within a reasonable time frame, guidelines for the
management of DR-TB are still largely based on expert opi-
nion. These remains, limited observational data on drug regi-
mens based on drugs for which there is often only limited
evidence of efficacy to date [22].
3. Special cases; XDR-TB/HIV
The coinfection of human immunodeficiency virus (HIV) and
XDR-TB complicates disease management and treatment out-
comes significantly and is mainly concentrated in sub-Saharan
Africa [12]. In South Africa where HIV diagnostic testing and
capacity for drug-susceptibility testing of MTB isolates is
robust, 40–80% of patients with XDR-TB are HIV infected
[23,24]. In the Russian Federation and Eastern Europe, XDR-
TB and HIV are often associated with injection drug use [25]. In
a Latvian cohort of 5,200 TB patients, the risk of developing
drug-resistant TB was double in HIV infection compared to
those without HIV [26]. Delay in XDR-TB diagnosis contributes
to poor treatment outcomes among HIV-infected patients.
Higher rates of extrapulmonary disease and smear-negative
TB in the HIV-infected patients limit diagnosis from sputum.
Effort in culturing the isolate is imperative, and aspiration of
lymph node and pleural fluid, as well as mycobacterial blood
and urine culture, have been of additive yield in diagnosing
XDR-TB in some HIV-infected cohorts [27].
Once TB is diagnosed in HIV-infected patients, international
consensus now favors antiretroviral (ART) naïve patients to
start ART within 2 weeks of starting treatment on TB if
CD4 < 50 cells/mm3 or if there is significantly advanced dis-
ease [28]. Second-line TB drug and ART interactions or additive
toxicities must also be monitored closely. For example, neu-
ropsychiatric effects of efavirenz and cycloserine/terizidone
have been recorded, but also ototoxicity, nephrotoxicity, and
electrolyte abnormalities of capreomycin and tenofovir, hema-
tological abnormalities related to earlier generation nucleo-
side reverse transcriptase inhibitors such as zidovudine and
linezolid, gastrointestinal side effects associated with many
ART drugs, thionamides and para-aminosalicylic acid, and oto-
toxicity from injectable agents has been frequent among
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studied cohorts of with HIV coinfection [29–31]. The integrase
inhibitor class of ART offers less interaction with second-line
TB medications but is not routinely available in many highly
TB endemic settings. There is accumulating evidence for the
safety and efficacy of bedaquiline in HIV-infected patients with
XDR-TB. In the South African early access program for beda-
quiline, the majority were HIV infected and of those remaining
on bedaquiline with 6 months of follow-up, 48 (76%) had
either culture converted or remained culture negative, a sig-
nificant improvement from historical norms [32]. Formal trials
of delamanid have to date enrolled very few patients with HIV
and none on ART [33]. The phase III trial of the completely oral
regimen of bedaquiline, pretomanid, and linezolid does
include HIV-infected patients but with CD4 count and ART
regimen-based exclusions limiting the number of those parti-
cipants who belong to the most important target group
(Clinical Trials Gov NCT02333799).
4. Prevention of XDR-TB during MDR-TB treatment
XDR-TB can be primarily transmitted from person to person or
secondary to the development through high bacillary load,
inadequate treatment (poor compliance, iatrogenic, drug
stock outs, programatic weakness), low body mass index, or
previous failures [34–38]. Prevention of the development of
drug-resistant TB is essential given the recent worldwide
increase in incidence. An example of important steps to pre-
vent XDR-TB come from Tugela Ferry in the KwaZulu-Natal
province of South Africa following sustained nosocomial and
community transmission of XDR-TB. Since the initial report of
XDR-TB in that community in 2006, considerable effort toward
infection control, intensified community-based TB and HIV
case finding and methods to decrease nosocomial transmis-
sion have curbed the local epidemic [23,39]. Nevertheless,
mortality remains associated with modifiable risk factors such
as lack of receipt of ART, suggesting further programmatic
interventions could improve treatment outcome [23,40].
Prevention can be strengthened through the programatic
expansion of treatment access and infection control strategies
and enhancement of basic healthcare infrastructure, which are
the cornerstones of a TB control program. Early awareness and
diagnosis of drug-resistant TB is essential to limit spread.
Recognition of risk factors for drug resistance would provide
useful clues; history of erratic past treatment, close contact
with drug-resistant TB, drug addiction, alcoholism, and migra-
tion from an area endemic for drug resistance [41]. New drugs
may also help to ameliorate the development of drug resis-
tance by more rapid sputum conversion and perhaps short-
ening the duration of treatment of TB [42]; however, adding
single active drugs to a failing regimen may lead to further
resistance. Furthermore, amplification of drug resistance may
occur while on apparently adequate treatment, given pro-
blems with malabsorption, altered drug metabolism or drug
interactions with concomitant antiretroviral therapy (ART), also
play a role [43,44].
5. Diagnosis of XDR-TB; DST/LPA
Since the introduction of molecular assays for the detection of
resistance, MDR-TB can generally be diagnosed readily within
hours [45] and this is the first step in early diagnosis of XDR-
TB. The GeneXpert MTB/RIF (Cepheid, Sunnyvale, USA) can
efficiently detect rifampicin resistance in most MDR-TB cases,
although in the first version of the test, especially in geo-
graphic areas with a low prevalence of MDR-TB, false-positive
tests are a problem [46]. This is associated with the detection
of a mutation not associated with rifampicin resistance. In the
new version of the GeneXpert cartridge (the ‘Ultra’), this pro-
blem should have been solved. In addition, the sensitivity in
the detection of MTB in ZN-negative sputa approaches that of
culture.
In comparison to the GeneXpert, the advantage of line
probe assays (LPA) in the detection of MDR-TB is that the
detected resistance mutations in most cases can be character-
ized. LPA allow a range of mutations in amplified DNA to be
screened by hybridization to a macro-DNA array [47].
Although these tests are technically more demanding and
require more expertise of the laboratory staff involved, this
offers a high degree of confidence in the diagnosis of MDR-TB
[48]. Nevertheless, it remains important to establish the posi-
tive and negative predictive value of LPA in each geographic
region where they are implemented [49]. Clinicians should not
be confronted only with the specific details of the results of
such tests, but with probabilities that MTB is resistant, or MDR.
Especially in the molecular detection of resistance against
fluoroquinolones and amino glycosides, detection of a muta-
tion in particular genomic targets of MTB does not always
imply resistance [49]; the predictive value of each mutation
differs significantly, and expertise in translating laboratory
findings into predictive values for clinicians is of the utmost
importance. For more information on genes and mutations,
we refer to more dedicated in-depth reviews [47]
The next step in the molecular detection of MDR- and XDR-
TB is whole-genome sequencing (WGS). Where in the current
molecular assays the most important genomic targets in MTB
are investigated for the presence of resistance mutations, in
the future around 25 genes that have ever been associated
with resistance against antituberculous drugs can be simulta-
neously examined for alterations in comparison to the native
sequence [50]. However, for many infrequently encountered
mutations, the predictive value needs to still be established,
especially for drugs not regularly used in treatment of resis-
tant TB.
The standard phenotypic drug susceptibility testing usually
involves testing of the inhibition of growth of MTB at the
critical concentration of the drugs. Nowadays, the MGIT960 is
the gold standard. However, treatment of MDR/XDR-TB should
be individualized and based on a combination of true mini-
mum inhibitory concentration (MIC) of drugs when testing the
MTB isolate in vitro and the plasma levels that can be achieved
in the respective patient [17,51,52]. This may become in reach
of more laboratories when cheaper MIC methods will be
standardized, like the 96-well Sensititre approach [53].
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6. Treatment of XDR-TB
Treatment of XDR-TB is a significant challenge given the lim-
ited data on treatment regimens and outcome. A meta-analy-
sis showed that the likelihood of cure seems to be lower than
in MDR-TB cases, between 18% and 67% [54]. These authors
also reported that the use of later-generation fluoroquino-
lones increased positive-treatment outcome by 40%, though
the susceptibility of the later-generation fluoroquinolones is
not routinely tested in all settings [54]. An analysis by Falzon
et al. showed that treatment success was highest when the
treatment regimen contained 6 drugs in the intensive phase
and at least four in the continuation phase [55]. In another
meta-analysis resistance to all injectables showed significantly
worse outcome compared to just resistance to a single drug of
this class; also the odds of treatment failure and death were
higher in all patients with XDR-TB and an additional resistance
[15,16,56].
The WHO recommends that the treatment regimen for
XDR-TB should contain pyrazinamide or ethambutol in case
MTB is susceptible. As shown by Jacobsen et al., a higher
generation fluoroquinolone of group A should be used, e.g.
moxifloxacin, levofloxacin, or gatifloxacin [19]. Also a second-
line injectable agent of group B should be used. The use of all
group C drugs that were not used in a previous regimen
should be applied. In the new drug classification of the WHO
(see Table 1), linezolid and clofazimine are promoted from
drugs with unclear efficacy to core drugs for MDR TB treat-
ment [19].
A recent study by Lee et al. showed 27 out of 38 patients
treated with linezolid still had negative sputum culture results
1 year after ending treatment [57]. Side effects appear to be
dose related, but the dose of linezolid can be decreased with-
out losing efficacy by using TDM [57–61].
Clofazimine added to the treatment of MDR/XDR-TB
showed good results; however, only 66% of the patients
with XDR-TB in this meta-analysis experienced favorable out-
come [62]. Preliminary data suggest that clofazimine improves
killing of persisting MTB and might therefore be useful to
prevent amplification and thus improve outcome.
Bedaquiline and delamanid are two newly approved anti-
TB drugs and are classified as group D2 drugs. Bedaquiline has
only been studied with culture conversion as primary outcome
parameter. Studies showed faster and more frequent culture
conversion in patients with MDR/XDR-TB compared to placebo
or using bedaquiline in treatment regimens [63–65]. A study
with delamanid for only 2 months showed earlier sputum
culture conversion as well [66]. Recently, the first report
using both drugs at the same time was published and this
was well tolerated.
Other drugs are categorized in group D3 or are more experi-
mental. The combination of meropenem-clavulanate for XDR-TB
was recently studied by Tiberi et al. showing the same culture
conversion rates for patients with XDR-TB compared to MDR-TB,
whereas only 6 patients out of 96 showed adverse events
[67,68]. Recently, the first studies using ertapenem in MDR/
XDR-TB patients were published. One study showed favorable
results in 3 out of 5 patients. The other two died shortly after
start of treatment [34]. Van Rijn et al. showed a favorable phar-
macokinetic/pharmacodynamics (PK/PD) profile for this drug in
MDR-TB patients. These obtained results and the easier possibi-
lity of administering this once per day dosed carbapenem at
home makes it a promising drug for the future [69].
Older drugs that have recently been restudied for TB are
co-trimoxazole and thioridazine. Alsaad et al. studied PK/PD
data of co-trimoxazole in 10 patients [70]. It was well tolerated,
though the free area under the concentration time curve/MIC
ratio of more than 25 was reached in only one patient.
Thioridazine, an old antipsychotic, showed promising results
in an Argentinian study in 2012 with cure in 10 out of 12
patients. This drug also might contribute to earlier sputum
conversion [71], due to its inhibitory effect on efflux pumps
and, hence, an accumulation of drug in the intracellular envir-
onment, resulting in cell death.
Recently, an 8 step approach for designing a XDR-TB regi-
men containing at least 5 active drugs used an online decision
tool to help physicians [72]
TDM and PK/PD science seems a valuable asset to optimize
drug exposure of individual drugs in relation to drug suscept-
ibility and patients’ tolerance to the drug [73]. Supportive
evidence from in vitro studies have shown a clear relation
between drug exposure and efficacy of treatment [74,75].
Moreover, acquired drug resistance could be reproduced in
these models. Clinical data to support TDM originates from
nonrandomized studies making it difficult to assess its true
value. However, its potential use for optimizing treatment in
individual patients is more and more appreciated in TB referral
clinics. Availability of simple tools to perform TDM may facil-
itate implementation in a programatic setting.
7. Potential role of host-derived biomarkers in
treatment guidance
As mortality rates are very high (around 30–80%) for XDR-TB,
there is an urgent need for measuring the response to its
treatment [54]. Optimizing treatment of XDR-TB cases is com-
plex as response is dependent on the infecting strain, host
metabolism, quality of the drugs, and compliance as well as
other factors. Most testing as currently used looks at one of
the factors. By using nonspecific host markers as surrogate
markers to quantify clinical response could help determine the
Table 1. The new WHO table for rifampicin resistant and MDR TB [19].
A. Fluoroquinolones # Levofloxacin
Moxifloxacin
Gatifloxacin
B. Second-line injectable agents # Amikacin
Capreomycin
Kanamycin













# For XDR-TB: use any drug from group A /B for which susceptibility is proven.
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response to treatment as a result of the interaction of all these
factors. Detailed studies focused on disclosure of patient bio-
marker with prognostic profiles to demonstrate the disease or
treatment success, but remained elusive [76,77]. None the less,
the kinetics of nonspecific disease-associated biomarkers are
increasingly recognized as having potential for the monitoring
of treatment success and could play a role in guiding the
therapy of complex (M[X]DR-TB) cases [78,79].
Host-derived markers are universally present in healthy and
disease individuals and the levels present in healthy indivi-
duals are in almost all cases already established. This is in
contrast to pathogen-derived markers (such as pathogen
DNA) which are only present in diseased individuals and in a
proportion of patients may be at barely detectable levels.
Therefore, although highly specific pathogen-derived biomar-
kers remain challenging to detect in all patients this combined
with the lack of highly specific antibodies associated with TB
infection is the main challenge for TB diagnostics. We suggest
that the kinetics of relatively less specific host biomarkers in
response to treatment may have advantages over monitoring
pathogen-derived biomarkers for many patients [80–82].
Multiple studies have demonstrated that there is a measur-
able and consistent response related to TB disease severity
and or the effect of therapy [83–88]. Early evidence suggests
that these responses will be informative before culture or
microscopic conversion is currently detected [78,79,89,90].
Thus, as measuring the response of host biomarker kinetics
has the potential to be both simple and rapid [91], measuring
biomarkers deserve attention. Moreover, biomarkers can also
be applicable to atypical cases (non-pulmonary and infections
in children).
Treatment of TB and particularly XDR-TB is complex and
long. In order to achieve universally good outcomes, even
with new regimens, personalization of treatment will likely
remain necessary for at least a proportion of patients.
Optimizing treatment in an individual approach has several
different aims: at one extreme some patients may be effec-
tively cured long before the end of the standard treatment
duration and may be exposed to toxic drugs for an unneces-
sarily long period. A second group of patients respond to
treatment but is not fully cured and is at risk of relapse after
the standard duration of treatment. Finally, for a variable
proportion of patients, host factors, drug levels achieved, or
bacterial resistance undermine the regimen and treatment
fails. Each of these issues can be addressed by bacterial phe-
notyping as well as monitoring of drug levels as discussed
elsewhere in this review. Whatever is measured, the ultimate
aim, to optimize treatment and treatment duration, is an
accurate ‘test of cure.’
As a fully standardized treatment that is optimal for all
patients is currently not available in order to minimize under,
or over, treatment an easily measurable biomarker signature
closely associated with successful cure is desirable. This
remains an area of intensive work [77,92,93]. Related to this
aim, it is worth noting that ‘successfully treated’ TB patients
are one of the primary groups at risk of developing active TB
again, with a risk of around 2000 per 100 000 person years
[94]. Disease-associated host biomarkers, useful for treatment
monitoring based on transcriptomic [95], metabolic [96], or
immunological markers [97] could thus also have a role in
screening high-risk groups including patients post treatment
or latently infected individuals to monitor increased chance of
break down to active disease.
The kinetics of the most promising biomarkers are now
being validated in independent studies and initial data sug-
gest that at least some the associations identified are repro-
ducible [78,79,90,97]. Differences in host marker responses
between sensitive and MDR-TB patients have been observed.
However, more detailed analysis as well as larger studies are
needed to accurately determine the sensitivity and specificity
of these responses and their link with particular drugs and
drug resistance profiles. Biomarkers that respond to effective
therapy would not only be valuable to individually optimize
therapy of MDR-TB and XDR-TB patients but also facilitate the
development of new treatments approaches [98]. Pre-vali-
dated biomarkers with reproducible kinetics in independent
studies must then be tested, in standardized formats, for
specificity and sensitivity and ultimately clinical impact in
larger cohorts. The collection and measurement of samples
suitable for this type of analysis should be considered when
planning larger treatment trials in order to advance treatment
monitoring from microscopy and culture toward rapid near-
patient measurements. To date, only few studies have been
able to contribute to the understanding of biomarkers during
TB treatment of which the most promising is the whole-blood
bactericidal activity is uniquely suited to assess the combined
effects of host-directed chemotherapy and antimicrobial che-
motherapy [5].
8. Design of XDR-TB care; a patient-centered
approach within a programatic framework
Programatic management of XDR-TB comprises four main
elements: case finding, treatment regimens, monitoring the
response to treatment, and selecting models of care [18].
Case finding of XDR-TB is generally a two-step approach:
diagnosing MDR-TB, followed by identifying resistance to FQ
or injectables (XDR if resistance to both drug classes is
detected, pre-XDR if resistance to one class is found). Ideally,
using molecular assays provide rapid results. Rapid diagnosis
of (pre-)XDR is becoming important especially now that the 9-
month ‘Bangladesh’ regimen is showing promise [99,100] and
results from a clinical trial are expected soon [101]. WHO
recently endorsed this short-course regimen for MDR-TB [19].
While this much shorter treatment has clear benefits over the
standard 20–24-month second-line regimen but is likely inef-
fective when (pre-)XDR-TB is treated. Patients are thus ideally
triaged for shortened or standard treatment using specific
molecular assays (LPA) but to date these have incomplete
sensitivity for both drug classes [102]. In addition for inject-
ables (kanamycin, amikacin, capreomycin), there is partial
cross-resistance with specific mutations being associated
with different levels of resistance to each of these drugs [5].
While standardization of non-(pre-)XDR MDR-TB treatment is
increasingly possible, the limited choice of effective drugs and
their unfavorable toxicity profile leave treatment regimens for
XDR-TB to be highly individualized. These will likely include
new drugs such as bedaquiline and delamanid. Programatic
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introduction of new TB drugs has several requirements includ-
ing assuring access; supply of chain management and training,
but also pharmacovigilance to detect toxicities not identified
in the relatively small phase II trials on which their conditional
approval was based [103]. Treatment response monitoring is
important not only for patient management but also for eval-
uating the treatment program through regular cohort analysis
(e.g. quarterly interim analysis) [18]. It should be based on
sputum culture, with cure defined as a patient who has com-
pleted treatment with no evidence of failure and three or
more consecutive negative cultures taken at least 30 days
apart after the intensive phase [104]. The definition of treat-
ment failure includes the need for a permanent regimen
change with at least two active anti-TB drugs for efficacy, to
halt resistance progression, and also to allow for redundancy
for potential adverse drug reactions. The latter has been chal-
lenged [105]. The lengthy treatment with often severe toxici-
ties call for social and psychological support for this often
vulnerable patient group [106]. Providing patient-centered
care, i.e. care that is respectful of and responsive to individual
patient preferences, needs, and values, and ensuring that
patient values guide all clinical decisions, is all the more
important to support patients and enhance treatment adher-
ence and completion [107]. In most XDR endemic settings,
substantial effort has to be made to achieve cure in substantial
proportion of the patients to prevent being discharged to the
community. A patient-centered care model should involve
individualized locations of care (community versus hospital,
etc.), regimens (TDM/MIC), multidiscplinary (psychological,
social and nutritional support), and novel aspects of adher-
ence. In situations of palliative care, safe infection control
practices are of utmost importance for transitioning a patient
into the community [24,54].
9. Conclusion
Although treatment of XDR-TB is challenging, the introduction
of intensified care that is based on individual case considera-
tion is the solution (Figure 1). Moreover, development of drug
resistance while receiving treatment for MDR-TB should
receive more attention. The intensified care of XDR-TB patients
starts with rapid diagnostics with molecular techniques fol-
lowed by sensitivity testing in combination with assessment of
drug exposure to advance the selection of the most appro-
priate treatment regimen. Daily observed therapy in
combination with early assessment of adverse events should
prevent adherence problems and cases lost to follow-up. If
novel drugs are incorporated in such an approach, treatment
success will likely increase to levels that are reached for those
with MDR-TB.
10. Expert commentary
As laid out above, the global threat of XDR-TB is real, with
many challenges that need to be overcome before significant
treatment success can be achieved. Currently, treatment out-
come results are still poor and may be worse still given the
relative lack of monitoring treatment. Van Altena et al.
reported good treatment results in MDR-TB patients with
individualized treatment using a mix of strategies [3]. The
backbone is the specialized TB centers that can deliver all
these strategies and should therefore play a major role in
the treatment of XDR-TB. Both when the patients are hospita-
lized or with a supervising role in case of ambulatory care.
The choice of drugs for the therapy of XDR-TB should be
based on drug susceptibility testing results. In high-burden
settings, where resources are often limited, molecular resis-
tance assays are used instead as they have a high throughput
and superior performance characteristics to conventional cul-
ture and drug-susceptibility testing [108]. However, individua-
lized treatment is based on true minimum inhibitory
concentration (MIC) of drugs when testing the MTB isolate
[17,51,52]. In addition to easy-to-implement MIC testing
[109], a central reference laboratory is crucial for optimal
treatment outcome in XDR-TB.
Individualizing treatment is based on pharmacokinetic
results of the drugs measured in a patient in relation to the
MIC of the isolate of that patient. Full curves can be easily
achieved when patients are admitted. In an ambulatory or
low-resource setting, limited sampling strategies can be
done using dry blood spots [110–112]. These filter paper
cards can be sent to central laboratories where the blood
drug concentrations can be analyzed by punching the blood
spot followed by subsequent extraction and analysis using
mass spectrometry [17].
Surgery as part of the treatment for XDR-TB is also an
individualized intervention. Selection criteria for surgical resec-
tion for MDR-TB were described by Iseman et al. and are still in
use [113]. Surgery is an option in patients when treatment


















• 3-4 drugs c
3 4
Figure 1. Overview of XDR-TB treatment. A: initiation phase, B: intensive phase, C: continuation phase, 1: treatment regimen based on GX and LPA, 2: treatment
regimen tailored to DST and TDM, 3: treatment regimen for continuation treatment, 4: duration of treatment, GX: GeneXpert, LPA: Line probe assay, TDM:
therapeutic drug monitoring, DST: drug susceptibility testing..
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enables resection. In case of persistent smear or culture, posi-
tivity surgery is performed to reduce the bacterial burden
even when accompanied with minimal bilateral nodes or infil-
trates [114]. An additional benefit of surgery is that the knowl-
edge of the penetration of the second-line anti-TB drugs into
the affected tissue can be increased [115,116]. However, facil-
ities to perform surgery on DR-TB patients remain critically
limited.
11. Five-year view
TB treatment is long and for M/XDR-TB even longer. Drugs
with sterilizing capacity are urgently needed to shorten treat-
ment. However, even with the current available drugs, one can
select patients that may benefit from a shorter treatment.
Patients without extensive disease and cavities responding
very well to treatment may qualify for a shorter treatment.
Biomarkers predictive of treatment response will be helpful to
support such a decision. Results of new studies hopefully
provide the required evidence to include differentiation in
treatment duration in WHO treatment guidelines.
As persistent smear or culture positivity is a serious problem,
other treatment options, in adjunct to new drugs or surgery,
should be looked at as well. The WHO has already mentioned
that when toxicity of an injectable agent is a limiting factor but
when considered effective, inhaling such an agent using a nebu-
lizer can be considered [19]. Little is known about the early
bactericidal activity of inhalation of anti-TB drugs. The first report
studying the effect of inhalation of colistin on transmission of TB,
however, unfortunately not an EBA study, was presented at the
Union conference in Vancouver in 2013 [117,118]. Theoretically,
inhalation of a drug can produce high concentrations at the site
of infection . Even in case of less susceptible bacteria, the inhaled
drugs can be used to reduce the bacterial load due to favorable
PK/PD parameters. As the first dried powder inhalation products
entered the market in 2010 for anti-pseudomonas treatment, we
expect more in the next 5 years.
A novel approach to try to improve TB treatment outcome
is to use therapeutic vaccines [119]. These vaccines modulate
the immune system to help it target persisting and dormant
TB bacilli thereby improving the sterilizing capacity of the
human immune system [120]. To date, several phase II and III
studies have been performed focusing on safety, immuno-
genicity, and improved treatment outcome. However, more
data is needed before therapeutic vaccines can become main-
stream treatment in TB treatment. The next 5 years will show if
therapeutic TB vaccines are as promising as expected.
Clinical evaluation and validation of the value of WGS is
urgently needed. It could potentially replace current available
diagnostic tests like LPA and DST. To claim this role, it should
become cheaper and more widely available. It should not only
be available at central level but also at intermediate level.
Moreover, results should be easily interpreted and represent
similar results as from LPA and DST. Compared to DST, it saves
a lot of time and is very helpful to tailor treatment including
dose to the individual patient. Before it can be implemented
in routine care, prospective studies providing supportive evi-
dence are required [121]. As WGS is currently a hot topic, in
5 years it is expected that it may set it first step in implemen-
tation studies for guiding treatment of drug resistant TB [122].
Key issues
● XDR-TB is defined by MDR-TB with additional resistance to,
a fluoroquinolone and a second-line injectable drug (ami-
kacin, kanamycin or capreomycin).
● Success rates for treatment of extensively drug resistant
tuberculosis (XDR-TB) are low due to limited treatment
options, delayed diagnosis and inadequate health care
infrastructure.
● The co-infection of human immunodeficiency virus (HIV)
and XDR-TB complicates disease management and treat-
ment outcomes significantly.
● Prevention of the development of XDR- TB is essential in
MDR-TB treatment
● The introduction of molecular assays for the detection of
resistance will help in early diagnosis of XDR-TB
● A step approach for designing a XDR-TB regimen containing
at least 5 active drugs followed by a tailoring to the dose base
on drug susceptibility and patients tolerance to the drug may
help to optimize treatment in individual patients.
● Biomarkers to provide information on treatment response
suitable to guide treatment duration are urgently needed.
● A more patient oriented approach by a multidisciplinary
team regarding diagnostics, drug selection and tailoring
and treatment evaluation will improve treatment outcome.
● Therapeutic vaccines to help the human immune system to
target persisting and dormant TB bacilli may improve ster-
ilizing capacity of current treatment.
● Clinical evaluation and validation of the value of whole
genome sequencing is urgently needed.
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